Proactiveinvestors recommends
Additional Information
Market: ASX
Sector: Pharmaceuticals
EPIC: BNO
Latest Price: 0.41  (-6.82% Descending)
52-week High: 0.74
52-week Low: 0.37
Market Cap: 141.34M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Bionomics
www.bionomics.com.au

Bionomics is a drug discovery and development company focused on new treatments for cancer and serious disorders of the central nervous system. Through application of its proprietary technology platforms, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy.

Full Bionomics profile here
Pdf

Bionomics makes further gains with anti-anxiety drug compound BNC210

2nd Feb 2010, 9:24 am

New data to be presented today by Bionomics (ASX: BNO) will show that its compound BNC210 exhibits an antidepressant effect - without symptoms of physical dependence. 

This supports previous research that showed that BNC210 does not cause abuse liability or development of tolerance.

Antidepressants have been shown to increase the formation and development of nerve cells in various regions of the brain and to also induce nerve growth in culture.

Studies of the effects of BNC210 on nerve cells in culture have shown that it too enhances their growth, consistent with antidepressant activity.

BNC210 Project Leader Dr Sue O’Connor will give a poster presentation at the Australian Neuroscience Society Annual Conference (ANS 2010) at 12pm today at the Sydney Convention Centre.

The title of the poster presentation is “The anxiolytic compound BNC210 exhibits an antidepressant effect without symptoms of physical dependence”.

Dr Sue O’Connor commented “The new results provide further support for the evaluation of BNC210 in humans for the treatment of anxiety and provide strong evidence for the potential utility of BNC210 in the treatment of depression”.

Abrupt cessation of current antidepressant medication may produce symptoms of withdrawal, such as changes in body weight, food intake or body temperature. Such changes signify physical dependence to the drug.

Importantly, these changes were not associated with BNC210 treatment of rats over 14 days and subsequent cessation of treatment when monitored over an 18 day period.

The data presented expands the evidence of antidepressant activity of BNC210, a novel compound which also displays potent activity in several models of anxiety.

The global antidepressant market reached sales of almost US$11 billion in 2008.

Blockbuster drugs such as Cymbalta [US$2.7B], Effexor, which is also used for the treatment of generalized anxiety disorder [US$3.9B], and Lexapro [US$2.29B] are the primary drug treatments.

Hence commercial potential for A$102 million market-capped, BNO's BNC210 compound is significant.

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.